Viyash Scientific acquires BioForLife for EUR 16.975 million to expand in Europe
Viyash Scientific Limited, through its subsidiary Alivira Animal Health Limited, has agreed to acquire 100% of BioForLife Italia S.r.l. for EUR 16.975 million to expand its footprint in the European companion animal health market. The deal involves EUR 15.0 million payable at closing and EUR 1.975 million as deferred consideration, with closing expected within three months subject to regulatory approvals.

*this image is generated using AI for illustrative purposes only.
Viyash Scientific Limited has signed a binding agreement to acquire 100% stake in BioForLife Italia S.r.l. for an aggregate consideration of EUR 16.975 million, strengthening its presence in the European companion animal health market. The transaction, executed through its step-down wholly owned subsidiary Alivira Animal Health Limited, is expected to close within three months from the execution of the agreement, subject to fulfilment of conditions precedent and regulatory approvals. This strategic move aims to capitalize on the growing Companion Animal Health Generics market and establish a platform in Italy, which ranks among the five largest animal health markets in Europe.
Acquisition Details
The following table summarises the key parameters of the transaction:
| Parameter: | Details |
|---|---|
| Target Company: | BioForLife Italia S.r.l. |
| Target Location: | Milan, Italy |
| Stake Acquired: | 100% |
| Deal Value: | EUR 16.975 million |
| Strategic Focus: | European Companion Animal Health Market |
Financial Structure and Approvals
The aggregate consideration of EUR 16.975 million is structured as EUR 15.0 million payable at closing and EUR 1.975 million as deferred consideration. The transaction is subject to fulfilment of applicable conditions precedent and receipt of statutory and regulatory approvals, including notification under Italian Golden Power Laws (Decree-Law No. 21/2012). The deferred consideration is expected to be settled within 12 months from closing or earlier upon the occurrence of the relevant trigger.
Strategic Rationale and Operations
BioForLife specializes in the development, commercialization, and distribution of products for veterinary use, including medicines, nutraceuticals, and testing kits. The company reaches over 80% of all veterinary clinics in Italy. Reported annual sales for CY 2025 were approximately EUR 9.0 million. The acquisition is intended to strengthen and scale Viyash Scientific's presence in Italy in the companion animal segment through an established front-end platform, customer reach, and product capabilities. The deal also facilitates the launch of new products from Alivira's pipeline in Italy and the expansion of the BioForLife range to other markets in Europe, the Middle East, Asia, and Latam.
Historical Stock Returns for Viyash Scientific
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.36% | -3.33% | +12.70% | +47.72% | +51.06% | +5.06% |
How will Viyash Scientific integrate BioForLife’s product portfolio with Alivira’s existing pipeline to accelerate growth in other European markets?
What specific regulatory challenges under the Italian Golden Power Laws could delay the transaction's closing?
Will this acquisition trigger further expansion strategies in other top European animal health markets?































